<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01290055</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00046406</org_study_id>
    <secondary_id>YFV Heavy Water Study</secondary_id>
    <secondary_id>5U19AI057266</secondary_id>
    <nct_id>NCT01290055</nct_id>
  </id_info>
  <brief_title>Turnover of Antigen Specific Lymphocytes After Immunization With the 17D Yellow Fever Vaccine</brief_title>
  <official_title>Turnover of Antigen Specific Lymphocytes After Immunization With the 17D Yellow Fever Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sri Edupuganti, MD MPH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Berkeley</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The yellow fever vaccine is a live, attenuated virus that results in a robust immune&#xD;
      response, especially in the T cell compartment. We have been studying immune responses to&#xD;
      live viral infections using the yellow fever vaccine as a model for a live viral infection.&#xD;
      In this study, we are interested in looking at the processing and lifespan of yellow fever&#xD;
      specific CD8 T cells.&#xD;
&#xD;
      We plan to accomplish this by measuring DNA replication and cell proliferation in humans&#xD;
      using a naturally occurring stable isotope called deuterium (D20). This technique has been&#xD;
      used to track the turnover of a number of human cell types in vivo. We plan to use D20&#xD;
      labeling to track YFV specific CD8+ T cells in human vaccinees who are positive for a&#xD;
      specific HLA type, HLA A202.&#xD;
&#xD;
      Deuterium labeled water (D2O), also known as heavy water is physically and chemically very&#xD;
      similar to ordinary drinking water. In water, two hydrogen atoms bond to an oxygen and create&#xD;
      H20. However in deuterated water, deuterium atoms replace the hydrogen atoms. Deuterium is a&#xD;
      form of hydrogen that has an extra neutron. This neutron gives the atom extra weight, hence&#xD;
      the name &quot;heavy water.&quot; This extra weight can be detected in the lab with very sensitive&#xD;
      instruments. Scientists have been using heavy water as a tracer to gain a better&#xD;
      understanding of animal and human metabolic rates. Deuterium is in fact already in the water&#xD;
      we drink daily. It is not radioactive, and it occurs naturally at a concentration of about 1&#xD;
      part per 5,000. Researchers have used heavy water since 1934 as a safe and effective tool in&#xD;
      clinical trials.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In general, T cell responses to viral infections occur in three distinct stages: expansion,&#xD;
      contraction and memory. During expansion, antigen-specific CD8+ T cells proliferate to&#xD;
      increase in numbers as well as acquire the ability to kill virus infected cells, i.e become&#xD;
      'effectors'. Once the virus is cleared, 90-95% of the effectors die. The small pool of&#xD;
      remaining cells differentiates gradually to become memory cells and provide life-long&#xD;
      protection. The rate of cell division is distinct in the generation of effectors and memory&#xD;
      cell maintenance. These concepts have been primarily derived from mouse studies. Human CD8+ T&#xD;
      cell turnover is not completely understood because of the lack of appropriate tools and&#xD;
      techniques suitable for human studies.&#xD;
&#xD;
      In this protocol, the researchers want to understand the lifespan and decay curve of effector&#xD;
      CD8+ T cells and the rate of homeostatic turnover of memory CD8+ (CD28+/- subsets) T cells&#xD;
      after 17D YFV immunization using an innovative method developed by Dr. Marc Hellerstein's&#xD;
      group (at the University of California, Berkeley) for measuring DNA replication and cell&#xD;
      proliferation in humans using a naturally occurring stable isotope called deuterium (2H).&#xD;
      This technique has been used to track the turnover of a number of human cell types in vivo.&#xD;
      The researchers of this study plan to use 2H labeling to track YFV specific CD8+ T cells in&#xD;
      human vaccinees (HLA-A2 positive participants only). The availability of a T cell epitope&#xD;
      (A2-NS4B214), a major component of the human YFV specific CD8+ T cell response, allows for&#xD;
      the longitudinal analysis of virus specific CD8+ T cells. The unique feature of this study is&#xD;
      that it allows for tracking of differentiation of YFV specific CD8+ T cells in humans. Thus,&#xD;
      the researchers can overcome the inherent limitations due to heterogeneity in cross-sectional&#xD;
      studies that involve bulk CD8+ T cells.&#xD;
&#xD;
      We plan to enroll 50 healthy, adult volunteers (18-45 of age) for Projects 1 and 2 to study&#xD;
      memory CD8 T cell responses. All subjects will receive the FDA approved YFV-17D vaccine (at&#xD;
      the FDA approved dose and route of administration). CD28 expression will be determined to see&#xD;
      if it is coupled to the generation and/or maintenance of YFV-specific memory CD8 T cells.&#xD;
      Phenotypic differences between CD28+ and CD28-_YFV-specific CD8 T cells will be studied to&#xD;
      determine differences in longevity. Gene expression profiles of CD28+ and CD28 YFV-specific&#xD;
      CD8 T cells will be determined. The influence of IL-7 and IL-15 on survival of YFV-specific&#xD;
      CD8 T cells will be studied. This information will be gained from YFV specific cells isolated&#xD;
      at Day 0, 14, 28 and 3 to 6 months, 1-2 years and &gt;5 years after vaccination.&#xD;
&#xD;
      The study will be conducted at the Hope Clinic of Emory Vaccine Center. Individuals who are&#xD;
      planning to travel to yellow fever endemic areas and who require the vaccine for travel&#xD;
      purposes as well as non-travelers will be recruited into the study. Potential participants&#xD;
      may be recruited from the Emory Travel Well Clinic or the CDC employee health or the Emory&#xD;
      University campus or the general population of metro Atlanta using radio and print&#xD;
      advertisements, electronic mailings, Internet postings, flyers, and posters. IRB approval&#xD;
      from Emory University will be obtained prior to the initiation of the study.&#xD;
&#xD;
      There will be a screening visit to determine the eligibility for the study. Signed informed&#xD;
      consent forms will be obtained prior to the initiation of study procedures. The inclusion and&#xD;
      exclusion criteria and a brief history and physical examination will be performed. In&#xD;
      addition, participants will be asked to undergo phlebotomy to determine the HLA type.&#xD;
      Participants who are positive for the HLA A202 allele, will be asked to participate in this&#xD;
      study. It is estimated that 25% of the Caucasian US population will be positive for this&#xD;
      allele. Participants who test negative for this allele will be offered other vaccine trials&#xD;
      that are being conducted at the Emory Hope clinic and their participation in this protocol&#xD;
      will end.&#xD;
&#xD;
      Prior to the administration of the yellow fever vaccine, the risk-benefit ratio of the&#xD;
      vaccine-related adverse events versus the risk of contracting yellow fever is determined.&#xD;
      Healthy individuals who have not been previously vaccinated with YFV vaccine will be included&#xD;
      in the study. Both female and male volunteers will be recruited.&#xD;
&#xD;
      We plan to enroll 50 healthy volunteers between 18 to 45 years of age. In order to meet these&#xD;
      enrollment goals, we may need to screen 200 subjects. All subjects will receive the FDA&#xD;
      approved YFV-17D vaccine (at the FDA approved dose and route of administration) once on day 0&#xD;
      of the study visit. Blood specimens will be obtained from the volunteers on Day 0, and on&#xD;
      scheduled time points post-vaccination. The total volume of blood drawn will not exceed the&#xD;
      Red Cross limit of 473mls in 56 days.&#xD;
&#xD;
      The study volunteers will be maintained on a 100ml - 150ml daily intake of 2H2O, with a goal&#xD;
      of maintaining 1.5-2% body water enrichment (assuming total body water turnover of ~3.5&#xD;
      liters per day in healthy, ambulatory subjects). Plasma and saliva samples will be obtained&#xD;
      during the 2H2O administration protocol for measurement of body 2H2O enrichment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tracking of deuterium labeled CD28+/- subsets of tetramer positive yellow fever specific CD8 T cells</measure>
    <time_frame>CD8 T cells will be measured on Day 0, 14, 28 and 3 to 6 months, 1-2 years and &gt;5 years after vaccination.</time_frame>
    <description>Tracking of deuterium labeled CD28+/- subsets of tetramer positive yellow fever specific CD8 T cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Turnover rates of DCs and monocytes in response to YFV-17D vaccination using D20</measure>
    <time_frame>CD8 T cells will be measured on Day 0, 14, 28 and 3 to 6 months, 1-2 years and &gt;5 years after vaccination.</time_frame>
    <description>Turnover rates of DCs and monocytes in response to YFV-17D vaccination using D20</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Yellow Fever</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In group 1, participants will receive the Yellow fever vaccine or YFV-17D and will be asked to drink Deuterium (70% enriched 2H2O) labeled water for 2 weeks. They will undergo phlebotomy on Day 0, 14, 28 and 3 to 6 months, 1-2 years and &gt;5 years after vaccination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In group 2, participants will receive the Yellow fever vaccine or YFV-17D and will be asked to drink Deuterium (70% enriched 2H2O) labeled water for 3 weeks. They will undergo phlebotomy on Day 0, 14, 28 and 3 to 6 months, 1-2 years and &gt;5 years after vaccination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Yellow fever vaccine or YFV-17D</intervention_name>
    <description>The YFV-17D (YF-VAXÂ®) manufactured by Sanofi Pasteur as a one-dose vial will be purchased from the manufacturer. Vaccine will be stored at the Emory Investigational Drug service between 2o to 8o C as per the manufacturer's instructions. It will be transported to the Hope clinic per the Standard Operating Procedures.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>YF-VAX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Deuterium (70% enriched 2H2O) labeled water</intervention_name>
    <description>70% enriched 2H2O will be obtained from Cambridge Isotope Laboratories (Andover, MA) in sterile 1L containers. An Emory IDS pharmacist will prepare sterile 50ml aliquots with a tamper seal which will be transported to the Hope clinic at room temperature.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>D20</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to understand and give informed consent&#xD;
&#xD;
          2. Age 18-45 years&#xD;
&#xD;
          3. Participants agree not to take any live vaccines 30 days before or after (14 days for&#xD;
             inactivated) yellow fever vaccination&#xD;
&#xD;
          4. Women of child bearing potential must agree to use effective birth control for the&#xD;
             entire duration of the study. A negative urine pregnancy test must be documented prior&#xD;
             to vaccination and prior to the initiation of drinking deuterium labeled water.&#xD;
&#xD;
          5. Must be positive for the HLA A202 allele (does not apply to Group 3 participants)&#xD;
&#xD;
          6. Must agree not to receive any other vaccination during the labeling period with heavy&#xD;
             water and in the first 28 days after receipt of yellow fever vaccination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Travel to or having lived in a country/area which is endemic for yellow fever (does&#xD;
             not apply to Group 3 participants)&#xD;
&#xD;
          2. History of previous yellow fever, West Nile, Dengue, St. Louis encephalitis, Japanese&#xD;
             encephalitis vaccination or infection (does not apply to Group 3 participants)&#xD;
&#xD;
          3. Any history of allergy to eggs, chicken or gelatin or to any previous vaccine (does&#xD;
             not apply to Group 3 participants)&#xD;
&#xD;
          4. A history of a medical condition resulting in impaired immunity (such as HIV&#xD;
             infection, cancer, particularly leukemia, lymphoma, use of immunosuppressive or&#xD;
             antineoplastic drugs or X-ray treatment). Persons with previous skin cancers or cured&#xD;
             non-lymphatic tumors are not excluded from the study.&#xD;
&#xD;
          5. History of HIV infection, Hepatitis B or Hepatitis C infection&#xD;
&#xD;
          6. History of any chronic medical conditions that are considered progressive (ex,&#xD;
             diabetes, heart disease, lung disease, liver disease, kidney disease, gastrointestinal&#xD;
             diseases and uncontrolled hypertension). Use of systemic immunosuppressive medications&#xD;
             (ex, prednisone) for 2 weeks or more in the past 3 months&#xD;
&#xD;
          7. History of excessive alcohol consumption, drug abuse, psychiatric conditions, social&#xD;
             conditions or occupational conditions that in the opinion of the investigator would&#xD;
             preclude compliance with the trial&#xD;
&#xD;
          8. Thymus gland problems (such as myasthenia gravis, DiGeorge syndrome, thymoma) or&#xD;
             removal of thymus gland or history of autoimmune disorder.&#xD;
&#xD;
          9. Recipient of a blood products or immune globulin product within 42 days of the&#xD;
             vaccination visit&#xD;
&#xD;
         10. Pregnant women and nursing mothers or women who are planning to become pregnant within&#xD;
             2 months after receiving the yellow fever vaccination&#xD;
&#xD;
         11. Any condition in the opinion of the investigator that would interfere with the proper&#xD;
             conduct of the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Srilatha Edupuganti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Hope Clinic of Emory Vaccine Center</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 3, 2011</study_first_submitted>
  <study_first_submitted_qc>February 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2011</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Sri Edupuganti, MD MPH</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Yellow Fever</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Memory T Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Yellow Fever</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

